TRT Symptoms Guide

Persistent low sex drive despite being on testosterone replacement therapy is one of the most common patient complaints. It frequently signals a hormonal imbalance rather than insufficient testosterone dose.

Persistent fatigue despite optimized testosterone levels suggests additional hormonal or metabolic issues that bloodwork can systematically identify. Energy complaints are the second most common reason TRT patients seek bloodwork re-evaluation.

Elevated estradiol on TRT or AAS produces a recognizable cluster of symptoms that are frequently misdiagnosed as other conditions. Confirming with bloodwork before starting an AI is essential — many "high estrogen" symptoms are actually caused by something else.

Androgenic alopecia can be accelerated by TRT and AAS, particularly in genetically susceptible men. The driving mechanism is DHT (dihydrotestosterone) acting on follicular androgen receptors, not testosterone itself.

Hematocrit elevation is the most common TRT-related bloodwork abnormality, affecting up to 40% of TRT users. It results from testosterone's direct stimulation of erythropoietin (EPO) production and red blood cell synthesis.

Oral 17-alpha alkylated anabolic steroids bypass first-pass hepatic metabolism via chemical modification, making them hepatotoxic. Monitoring AST, ALT, and GGT is essential during any oral AAS cycle.

Sleep quality commonly deteriorates during TRT, particularly with high doses or certain compounds. The most clinically significant mechanism is testosterone-driven worsening of sleep apnea, which is frequently undiagnosed in TRT patients.

Mood instability, irritability, anxiety, or depression on TRT can stem from multiple hormonal mechanisms. Bloodwork is critical because the treatment differs entirely depending on whether the driver is high estradiol, low estradiol, testosterone peaks, or prolactin.

Excess water retention (edema) is common in the early weeks of TRT and during high-dose AAS use. It ranges from cosmetically bothersome to clinically significant when affecting blood pressure or cardiopulmonary function.

Long-term AAS use is associated with accelerated cardiovascular disease through multiple mechanisms including left ventricular hypertrophy, lipid dysregulation, endothelial dysfunction, and thrombotic risk from elevated hematocrit. Bloodwork alone cannot capture full cardiovascular risk — imaging is also needed.